BR112020020708A8 - Derivados da ureia cíclica fundidã como antagonista crhr2 - Google Patents

Derivados da ureia cíclica fundidã como antagonista crhr2

Info

Publication number
BR112020020708A8
BR112020020708A8 BR112020020708A BR112020020708A BR112020020708A8 BR 112020020708 A8 BR112020020708 A8 BR 112020020708A8 BR 112020020708 A BR112020020708 A BR 112020020708A BR 112020020708 A BR112020020708 A BR 112020020708A BR 112020020708 A8 BR112020020708 A8 BR 112020020708A8
Authority
BR
Brazil
Prior art keywords
crhr2
urea derivatives
furnished
cyclic urea
crhr1
Prior art date
Application number
BR112020020708A
Other languages
English (en)
Other versions
BR112020020708A2 (pt
Inventor
Ohmi Masashi
Matsushita Takeshi
Ando Kazuo
Yamaguchi Ryuichi
Fukumoto Yutaka
Magara Ryohei
Yamagishi Tatsuya
Takefuji Mikito
Original Assignee
Raqualia Pharma Inc
National Univ Corporation Tokai National Higher Education And Research System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Raqualia Pharma Inc, National Univ Corporation Tokai National Higher Education And Research System filed Critical Raqualia Pharma Inc
Publication of BR112020020708A2 publication Critical patent/BR112020020708A2/pt
Publication of BR112020020708A8 publication Critical patent/BR112020020708A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A presente invenção refere-se a derivados da ureia cíclica fundida que têm atividades antagônicas contra o CRHR1 e CRHR2, e que são úteis no tratamento ou prevenção de distúrbios e doenças nos quais o CRHR1 e/ou CRHR2 estão envolvidos. A invenção também se refere a composições farmacêuticas compreendendo esses compostos e o uso desses compostos e composições na prevenção ou tratamento de tais doenças nas quais o CRHR1 e/ou CRHR2 está envolvido.
BR112020020708A 2018-04-09 2019-04-09 Derivados da ureia cíclica fundidã como antagonista crhr2 BR112020020708A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862654628P 2018-04-09 2018-04-09
US62/654,628 2018-04-09
PCT/JP2019/015392 WO2019198692A1 (en) 2018-04-09 2019-04-09 Fused cyclic urea derivatives as crhr2 antagonist

Publications (2)

Publication Number Publication Date
BR112020020708A2 BR112020020708A2 (pt) 2021-01-12
BR112020020708A8 true BR112020020708A8 (pt) 2022-10-18

Family

ID=68164246

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112020020708A BR112020020708A8 (pt) 2018-04-09 2019-04-09 Derivados da ureia cíclica fundidã como antagonista crhr2

Country Status (11)

Country Link
US (1) US11802120B2 (pt)
EP (1) EP3774739B1 (pt)
JP (1) JP7357932B2 (pt)
KR (1) KR102590854B1 (pt)
CN (1) CN111868037B (pt)
BR (1) BR112020020708A8 (pt)
CA (1) CA3094609A1 (pt)
ES (1) ES2917634T3 (pt)
MX (1) MX2020010568A (pt)
TW (1) TWI822754B (pt)
WO (1) WO2019198692A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021145401A1 (en) * 2020-01-15 2021-07-22 Raqualia Pharma Inc. Spiroheterocyclic derivatives as crhr2 antagonist
EP3901152A1 (en) * 2020-04-23 2021-10-27 F. Hoffmann-La Roche AG Kv3 enhancers for the treatment of cognitive disorders
EP4222142A1 (en) * 2020-09-30 2023-08-09 RaQualia Pharma Inc. 3-hydroxyoxindole derivatives as crhr2 antagonist
WO2022228365A1 (zh) * 2021-04-27 2022-11-03 南京明德新药研发有限公司 六元杂芳并脲环的衍生物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999057103A1 (fr) 1998-04-30 1999-11-11 Nippon Chemiphar Co., Ltd. Derive d'imidazole condense et agent therapeutique permettant de traiter une maladie du foie
BR0209267A (pt) 2001-04-30 2004-06-15 Glaxo Group Ltd Pirimidinas fundidas como antagonistas do fator de liberação de corticotropina (crf)
WO2002100863A1 (en) * 2001-06-12 2002-12-19 Glaxo Group Limited Corticotropin releasing factor antagonists
JP2007161585A (ja) 2004-06-25 2007-06-28 Taisho Pharmaceut Co Ltd 環状アミノ基で置換されているピロロピリミジン及びピロロピリジン誘導体
WO2006044821A1 (en) * 2004-10-19 2006-04-27 Sb Pharmco Puerto Rico Inc. Crf receptor antagonists and methods relating thereto
WO2007149938A2 (en) 2006-06-21 2007-12-27 The Salk Institute Biological Studies Methods for promoting hair growth
US8273900B2 (en) * 2008-08-07 2012-09-25 Novartis Ag Organic compounds
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP5748777B2 (ja) * 2010-02-02 2015-07-15 ノバルティス アーゲー Ｃｒｆ受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2013160317A2 (en) * 2012-04-23 2013-10-31 Holsboermaschmeyer Neurochemie Gmbh Crhr1 antagonists for use in the treatment of patients having crh overactivity

Also Published As

Publication number Publication date
EP3774739B1 (en) 2022-05-11
WO2019198692A1 (en) 2019-10-17
JP2021521142A (ja) 2021-08-26
BR112020020708A2 (pt) 2021-01-12
EP3774739A1 (en) 2021-02-17
KR102590854B1 (ko) 2023-10-18
US20210078975A1 (en) 2021-03-18
EP3774739A4 (en) 2021-08-25
CN111868037A (zh) 2020-10-30
TW201945355A (zh) 2019-12-01
CN111868037B (zh) 2023-10-13
JP7357932B2 (ja) 2023-10-10
ES2917634T3 (es) 2022-07-11
CA3094609A1 (en) 2019-10-17
TWI822754B (zh) 2023-11-21
KR20200135834A (ko) 2020-12-03
US11802120B2 (en) 2023-10-31
MX2020010568A (es) 2020-10-22

Similar Documents

Publication Publication Date Title
BR112020020708A8 (pt) Derivados da ureia cíclica fundidã como antagonista crhr2
BR112018012756A2 (pt) compostos heterocíclicos como imunomoduladores
BR112015016315A2 (pt) fluoro-[1,3]oxazinas como inibidores de bace1
MY196909A (en) Boronic acid derivatives and therapeutic uses thereof
NZ733174A (en) Quinazoline derivatives used to treat hiv
BR112015021888A8 (pt) inibidores de dna-pk, seus usos e composição farmacêutica
BR112015028879A8 (pt) compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos
CL2020001762A1 (es) Formas cristalinas del derivado de 4-pirimidinsulfamida de aprocitentán. (divisional solicitud 201902464)
BR112015019412A8 (pt) inibidores de bace1, seus usos, e composição farmacêutica
BR112018071408A2 (pt) “composto inibidor de rip2 quinase, composição farmacêutica, usos de um composto e de uma combinação, e, combinação
BRPI1014902A2 (pt) composto antagonista de p2x7r, sua composição e seus usos
BR112019024830A2 (pt) inibidores de bcl6 derivados de benzimidazolona
BR112019001768A2 (pt) moduladores do receptor de spiro-lactamas nmda e usos dos mesmos
BR112018071831A2 (pt) composições anti-irritantes sinérgicas de taurina e aloé e métodos
UY37971A (es) Derivados de indol macrocíclicos sustituidos
PH12019500188A1 (en) Piperidine cxcr7 receptor modulators
BR112014028813A2 (pt) 5-amino[1,4]tiazinas como inibidores bace1
BR112020007589A8 (pt) Derivados de benzimidazol e seus usos
BR112016022722B8 (pt) Composto, composição farmacêutica que o comprende e uso do mesmo
ZA202001295B (en) Thiazolopyridine derivatives as adenosine receptor antagonists
PH12019502850A1 (en) AMIDE DERIVATIVES AS Nav1.7 AND Nav1.8 BLOCKERS
BR112015031846A8 (pt) derivados de estratrientiazol, seus usos, e composição farmacêutica
ZA202001780B (en) Bezimidazole derivatives as adenosine receptor antagonists
MX2021007425A (es) Derivados heterociclicos como bloqueadores de nav1.7 y nav1.8.
EA202191955A1 (ru) Таблетированные составы с модифицированным высвобождением, содержащие ингибиторы фосфодиэстеразы

Legal Events

Date Code Title Description
B350 Update of information on the portal [chapter 15.35 patent gazette]
B25A Requested transfer of rights approved

Owner name: RAQUALIA PHARMA INC. (JP)

B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]